Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.08

-2.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6830)	7/30/2002 4:13:34 PM
From: Ian@SI	Read Replies (2) of 52153

...what I call revolving door repricing. Not quite the same thing. Options issued to the departing executive will expire worthless rather than being returned to the treasury. The new guy gets new options reducing the total amount available for issue. It's unlikely that shareholders will approve any new allotments any time soon. I also think that repricing should be banned. ...until the company is willing to reimburse me for any loss I took as an owner of their company by buying too soon. To the extent that they have the shareholders' blessing they can always issue new options any time they so choose.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next